Clinical Trials
105 trialsTesting the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
MAGE-A4ᶜ¹º³²T for Multi-Tumor
USWM, LLC (dba US WorldMeds)
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
COD
National Cancer Institute (NCI)
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
National Cancer Institute (NCI)
First in Human Study of M1069 in Advanced Solid Tumors
EMD Serono
PRIMING
Royal Marsden NHS Foundation Trust
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
A Study of LY3039478 in Participants With Advanced Cancer
Eli Lilly and Company
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
University of California, San Diego
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
Amgen
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
Boehringer Ingelheim
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
Daiichi Sankyo
REGONIVO
National Cancer Center Hospital East
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
Altor BioScience
QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
NantBioScience, Inc.
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
QUILT-3.028: Study of haNKâ„¢ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors
ImmunityBio, Inc.
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
Boehringer Ingelheim
V938-001
Merck Sharp & Dohme LLC
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Pfizer
A Study of LY3022855 In Participants With Breast or Prostate Cancer
Eli Lilly and Company
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
Wake Forest University Health Sciences
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Pfizer
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
EMD Serono
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
Synlogic
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Ipsen
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
Daiichi Sankyo
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
MK-8353-014
Merck Sharp & Dohme LLC
Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery
Wake Forest University Health Sciences
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Herlev Hospital
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
National Cancer Institute (NCI)
Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis
Barbara Ann Karmanos Cancer Institute
A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
Eli Lilly and Company
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Pfizer
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
SENTINEL
GSO Global Clinical Research BV
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
SCRI Development Innovations, LLC